Savara Inc Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Savara Inc (SVRA) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $3.27 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-06.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2017-03-06
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2014-12-31 was $0.00.
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2014-09-30 was $0.00.
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2014-06-30 was $110.00K.
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2014-03-31 was $3.16M.
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for fiscal 2014 was $3.27M.
- Savara Inc business combination, consideration transferred, equity interests issued and issuable for fiscal 2013 was $0.00.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 0 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 0 month as first filed | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $0.00 derived: sum of 2 quarters · filed 2017-03-06 | $110.00K derived: sum of 3 quarters · filed 2017-03-06 | $3.27M 10-K · filed 2017-03-06 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $110.00K derived: sum of 2 quarters · filed 2015-11-12 | $3.27M 10-Q · filed 2015-11-12 | $3.27M derived: sum of 4 quarters · filed 2015-11-12 | ||
| 2014-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $3.27M 10-Q · filed 2015-08-12 | $3.27M derived: sum of 3 quarters · filed 2015-08-12 | |||
| 2014-03-31 | $3.16M 10-Q · filed 2015-05-11 | $3.16M derived: sum of 2 quarters · filed 2015-05-11 | ||||
| 2014-02-27 | $3.30M 10-Q · filed 2015-05-11 | $3.20M 10-Q · filed 2014-05-05 | ||||
| 2013-12-31 | -$250.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-24 | $0.00 10-K · filed 2015-03-24 | ||||
| 2013-09-30 | $250.00 10-Q · filed 2014-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |